Dermatomyositis and polymyositis (myositis) trials in Germany

In Germany 24 Also abroad 124

24 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 13 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Taking people
A Study of AZD0120 in Autoimmune Diseases
Where
Berlin, Erlangen, Hamburg, Jena, Mainz, Würzburg
Age
18 years to 75 years
People
27 worldwide
Run by
AstraZeneca
See details and how to joinNCT07295847
Phase 1Taking people
Phase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
Where
Dresden, Erlangen, Goettingen, Luebeck, Rüdersdorf, Tuebingen
Age
18 years and over
People
78 worldwide
Run by
Chugai Pharmaceutical Co. Ltd.
See details and how to join2024-511346-39-00
Phase 3Not yet taking people in Germany
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
Where
Bad Bramstedt, Berlin, Cologne, Erlangen, Freiburg im Breisgau, Halle, Jena, Kirchheim unter Teck, Tübingen, Würzburg
Age
18 years and over
People
270 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07789015 · EU 2026-526365-24-00
Phase 1Taking people
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Where
Augsburg, Cologne, Hanover, Mainz
Age
18 years to 70 years
People
80 worldwide
Run by
CRISPR Therapeutics
See details and how to joinNCT06925542
Phase 1Taking people
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Where
Cologne, Erlangen, Magdeburg
Age
18 years to 70 years
People
72 worldwide
Run by
AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00
Phase 3Enrolling by invitation
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Where
Berlin, Duesseldorf, Goettingen, Hamburg, Herne, Mannheim, Sendenhorst, Tuebingen, Ulm
Age
18 years and over
People
240 worldwide
Run by
argenx
See details and how to joinNCT05979441 · EU 2022-502851-79-00
Phase 2/3Taking people
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
Where
Berlin, Frankfurt Am Main, Goettingen
Age
6 years to 75 years
People
74 worldwide
Run by
Cabaletta Bio
See details and how to joinNCT06154252 · EU 2025-521145-24-01
Phase 1Not yet taking people in Germany
A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
Where
Berlin, Erlangen, Magdeburg, Würzburg
Age
18 years and over
People
60 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07873931
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Where
Bad Nauheim, Berlin, Bonn, Freiburg im Breisgau, Herne, Munich, Tuebingen
Age
18 years and over
People
84 worldwide
Run by
AstraZeneca AB
See details and how to join2023-504022-19-01
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Where
Bad Nauheim, Berlin, Bonn, Freiburg im Breisgau, Herne, München, Tübingen
Age
18 years to 75 years
People
240 worldwide
Run by
AstraZeneca
See details and how to joinNCT06455449
Phase 3Taking people
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Where
Erlangen, Munich, Ulm
Age
18 years and over
People
318 worldwide
Run by
Pfizer
See details and how to joinNCT05895786 · EU 2022-502739-20-00
Phase 1Taking people
A Phase 1 Study of the Safety and Preliminary Efficacy of CTX112 in Adult Subjects With Refractory Autoimmune Disease.
Where
Augsburg, Cologne, Frankfurt Am Main, Hanover, Mainz
Age
18 years and over
People
51 worldwide
Run by
CRISPR Therapeutics AG
See details and how to join2024-518528-54-00
Phase 2Taking people
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
Where
Bonn, Munich
Age
18 years and over
People
90 worldwide
Run by
Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00
Phase 1Taking people
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Where
Dresden, Erlangen, Goettingen, Rüdersdorf, Tuebingen
Age
18 years to 85 years
People
144 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00
Phase 1Enrolling by invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Where
Erlangen, Göttingen, Lübeck, Sachsen, Tübingen
Age
18 years to 85 years
People
144 worldwide
Run by
Chugai Pharmaceutical
See details and how to joinNCT06723106
Phase 1Taking people
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
Where
Berlin, Dresden, Duesseldorf, Hamburg, Kiel
Age
18 years and over
People
125 worldwide
Run by
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00
Phase 1Taking people
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Where
Cologne, Duesseldorf, Jena, Mainz
Age
18 years to 70 years
People
44 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00
Phase 2/3Taking people
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
Where
Berlin, Bochum, Hamburg, Hanover
Age
18 years and over
People
70 worldwide
Run by
Kyverna Therapeutics
See details and how to joinNCT07403188 · EU 2024-511198-31-00
Phase 1/2Taking people
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
Where
Erlangen
Age
18 years and over
People
24
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT06347718 · EU 2024-516819-24-00
No phaseEnrolling by invitation
Development and Validation of the FBIndex to Determine the Risk of Falls for Patients With Neuromuscular Disorders
Where
München
Age
18 years to 65 years
People
108
Run by
LMU Klinikum
See details and how to joinNCT06605612
No phaseTaking people
Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy
Where
Bonn
Age
18 years and over
People
120
Run by
University of Bonn
See details and how to joinNCT07150000
No phaseEnrolling by invitation
The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.
Where
Bad Feilnbach
Age
65 years to 65 years
People
30
Run by
LMU Klinikum
See details and how to joinNCT07072676
No phaseTaking people
AYLo - AutoimmunitY and Loss of y
Where
Bonn
Age
50 years and over
People
500
Run by
University of Bonn
See details and how to joinNCT06696027
Phase 2Taking people
Safety and efficacy of low-dose interleukin-2 therapy in chronic inflammatory barrier diseases (IL-2-ID)
Where
Luebeck
Age
18 years and over
People
112
Run by
Universitaetsklinikum Schleswig-Holstein AöR
See details and how to join2023-510297-14-00